Company news
Imugene Ltd news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Change of Director's Interest Notice x2 - KD & JD
November 20, 2026
Application for quotation of securities - IMU
November 19, 2026
Final Director's Interest Notice - LR
November 18, 2026
Notification of cessation of securities - IMU
November 18, 2026
Imugene Receives $2.1M R&D Tax Refund
November 15, 2026
Director Resignation and Committee Changes
November 10, 2026
Results of 2026 Annual General Meeting
November 10, 2026
AGM Presentation
November 10, 2026
Imugene selected for Poster Presentation at 2026 ASH Meeting
November 4, 2026
Positive amendments to Convertible Notes
November 2, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
October 29, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
October 29, 2026
Further Responses in azer-cel Phase 1b Trial
October 18, 2026
Further Responses in azer-cel Phase 1b Trial
October 18, 2026
Notification of cessation of securities - IMU
October 16, 2026
Application for quotation of securities - IMU
October 14, 2026
Application for quotation of securities - IMU
October 13, 2026
Notice of Annual General Meeting/Proxy Form
October 8, 2026
Dr John Le Gall appointed Chief Medical Officer
October 6, 2026
azer-cel BTKi Cohort Reports new Complete & Partial Response
October 4, 2026
Change of Director's Interest Notice - JD
October 1, 2026
Application for quotation of securities - IMU
September 8, 2026
Cleansing Notice
September 1, 2026
Application for quotation of securities - IMU
September 1, 2026
Change of Director's Interest Notice x4
September 1, 2026
Corporate Governance Statement and Appendix 4G
August 28, 2026
Appendix 4E and Annual Report
August 28, 2026
Notice under section 708A(12C)(e) of the Corporations Act
August 27, 2026
Notice of Initial Substantial Holding for IMU
August 27, 2026
Becoming a substantial holder for IMU
August 26, 2026
Notification regarding unquoted securities - IMU
August 26, 2026
Notification of cessation of securities - IMU
August 26, 2026
Application for quotation of securities - IMU
August 25, 2026
Amendment of Convertible Notes
August 20, 2026
Results of Extraordinary General Meeting
August 18, 2026
Letter To Shareholders
August 9, 2026
Expiry Of Listed Options
August 5, 2026
Final Director's Interest Notice - LC
July 31, 2026
Notification of cessation of securities - IMU
July 31, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
July 30, 2026
Third response in concurrent BTKi Cohort of azer-cel Trial
July 26, 2026
$11.1 Million Placement Completed to Advance azer-cel
July 6, 2026
New Complete Response in the Concurrent BTKi azer-cel Cohort
June 30, 2026
First Complete Response in Concurrent BTKi azer-cel Cohort
June 29, 2026
Azer-cel Granted FDA Fast Track Designation for CLL and MZL
June 8, 2026
First Patient in BTKi Combination Cohort of azer-cel study
May 27, 2026
Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract
May 21, 2026
Diamond Equity Research Releases Update Note on Imugene Limited (ASX: IMU)
May 20, 2026
Prospectus
March 17, 2026
$20M placement and SPP, convertible notes amended
March 11, 2026
Decks
The 5 newest of 54 decks. Every deck is listed under its year.
- Investor Presentation (July 2026)
Investor deck · 29 slides · Jul 7, 2026
- Investor Presentation (March 2026)
Investor deck · 31 slides · Mar 11, 2026
- Technical Presentation (February 2026)
Technical · 15 slides · February 2026
- Shareholder Meeting (November 2025)
Shareholder meeting · 16 slides · Nov 13, 2025
- Shareholder Meeting (August 2025)
Shareholder meeting · 6 slides · Aug 20, 2025